Loading company…
ID 400327008 · FY 2022–2023 · 2 years
1.2 კომპანიის ძირითად საქმიანობას წარმოადგენს: - საბითუმო ვაჭრობა ფარმაცევტული საქონლით თავისუფალ ინდუსტრიულ ზონაში 1.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2022 | 2023 |
|---|---|---|
| Margins | ||
| Gross Margin | 45.0% | 37.0% |
| EBITDA Margin | 44.5% | 36.7% |
| EBITDAR | 5,055 | 8,765 |
| EBITDAR Margin | 44.9% | 36.9% |
| EBIT Margin | 44.5% | 36.6% |
| Net Profit Margin | 43.2% | 37.4% |
| Operating Expense % of Sales | 0.4% | 0.4% |
| Returns | ||
| Return on Assets (ROA) | 55.2% | 46.2% |
| Return on Equity (ROE) | 100.0% | 64.8% |
| ROIC [EBIT / Invested Capital] | 120.0% | 63.5% |
| Leverage & liquidity | ||
| Debt-to-Assets | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x |
| Equity-to-Assets | 55.2% | 71.2% |
| Net Debt | -682 | -1 |
| Cash & Equivalents | 682 | 1 |
| Total Debt | N/A | N/A |
| Efficiency & working capital | ||
| Inventory Turnover | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A |
| Receivables Turnover | 1.64x | 1.32x |
| Days Sales Outstanding (DSO) | 222.4 | 276.9 |
| Payables Turnover | 1.57x | 2.70x |
| Days Payable Outstanding (DPO) | 232.7 | 135.4 |
| Cash Conversion Cycle | -10.2 days | 141.5 days |
| Asset Turnover | 1.28x | 1.23x |
| Cash flow & dividends | ||
| Operating Cash Flow | 691 | -615 |
| Free Cash Flow (OCF − Capex proxy) | 691 | -615 |
| Cash Conversion (OCF / EBITDA) | 13.8% | -7.1% |
| Dividends Declared | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.